Pfizer
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
AMG
|
Business associate |
5
|
1 | |
|
person
Durata Therapeutics
|
Spin out |
5
|
1 |
HOUSE_OVERSIGHT_026761.jpg
A Forbes article reporting on the Swedish American Life Science Summit (SALSS) in Stockholm, which gathered global scientists and investors to discuss innovations in healthcare such as robotics, nanotechnology, and cancer research. The article highlights the shift in the pharmaceutical industry towards collaboration with startups and "impact investing" to address chronic diseases in an aging population, featuring insights from various industry leaders.
HOUSE_OVERSIGHT_026750.jpg
This document is a program page or partner list for the 2017 Swedish American Life Science Summit (SALSS). It lists corporate partners (including Pfizer, AstraZeneca, and Embassies) and the leadership team, including Founder Barbro C. Ehnbom. The Senior Advisory Board includes notable figures such as Dr. Robert Langer (MIT) and Dr. William A. Haseltine. The document originates from a House Oversight Committee release (HOUSE_OVERSIGHT_026750).
HOUSE_OVERSIGHT_026749.jpg
This document is a program page for the SALSS (Swedish-American Life Science Summit) 2017. It lists the schedule for the 'HealthTech Showroom', exhibiting partners (such as Elekta and CellInk), and details the 'Rising Star Award' featuring HKH Daniel, Prince of Sweden. It also lists the jury members for the award and various investors attending the 'SALSS Investor Forum'. The document bears a House Oversight stamp.
HOUSE_OVERSIGHT_023365.jpg
This document is a page from a Table of Contents and Table of Authorities for a legal filing related to the 'In re: Terrorist Attacks on September 11, 2001' litigation. It outlines legal arguments regarding the Alien Tort Statute (ATS), the Torture Victim Protection Act, and negligence claims against defendants alleged to have materially supported al-Qaeda, specifically mentioning 'NCB' (National Commercial Bank) and 'Sovereign Defendants.' The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional production, likely related to investigations into financial networks supporting terrorism.
HOUSE_OVERSIGHT_023080.jpg
This document is page 12 of a Bank of America Merrill Lynch Equity Strategy report dated January 29, 2017. It analyzes the financial implications of corporate cash repatriation and the proposed 'border adjustment tax' under the Trump administration. The text discusses offshore holdings of major tech and pharma companies (AAPL, MSFT, etc.) and references comments by Donald Trump and Sean Spicer regarding tax policy. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to the House Oversight Committee.
HOUSE_OVERSIGHT_023076.jpg
This document is a page from a Bank of America Merrill Lynch equity strategy report dated January 29, 2017. It analyzes the impact of the 2004 Homeland Investment Act (HIA), specifically detailing how 15 major corporations (including Pfizer, Merck, and HP) repatriated billions in offshore funds but subsequently reduced US workforces and R&D spending while increasing share buybacks. The document includes data tables sourced from the IRS and a US Senate Permanent Subcommittee on Investigations survey, stamped with the file ID HOUSE_OVERSIGHT_023076.
HOUSE_OVERSIGHT_015673.jpg
This document appears to be page 2 of a CV for a high-level medical administrator or executive (likely associated with Mount Sinai). It details their work as a Global Health Project Leader (2002-2015), Director of Strategic Initiatives (2001-2002), and Assistant Dean (1998-2001). Key activities include coordinating Haiti earthquake relief with the Clinton Foundation and Partners in Health, negotiating the use of a Honeywell corporate jet, and managing significant medical missions in Liberia.
HOUSE_OVERSIGHT_015671.jpg
This document is a professional biography for Robin Solomon, detailing her extensive career at Mount Sinai Medical Center. It highlights her role in Donor Relations and Trustee Services, where she collaborated with major financial and legal firms (including Goldman Sachs) to generate over $20 million annually. The document also outlines her global health initiatives, including work with the Clinton office for Haiti relief and President Sirleaf in Liberia, as well as her background in clinical research and nursing. The document is stamped 'HOUSE_OVERSIGHT_015671', indicating it is part of a Congressional investigation.
HOUSE_OVERSIGHT_015399.jpg
The document appears to be a script page from the television show 'Seinfeld', specifically featuring dialogue about the drug Viagra and Pfizer stock. It depicts a conversation between George Costanza and his parents regarding the cost of the pills, followed by a scene where Kramer tells Jerry Seinfeld he is getting rich off Pfizer stock. The document bears a 'HOUSE_OVERSIGHT' footer, indicating it was likely included as an attachment or exhibit in a document production for a congressional investigation.
HOUSE_OVERSIGHT_024044.jpg
This document is page 33 of a confidential investment memorandum for a fund named 'New Leaf' (likely New Leaf Venture Partners). It details the fund's strategy regarding late-stage commercialization and small-cap public biotech companies, citing specific successful exits like Acadia Pharmaceuticals (2.5x) and InterCept Pharmaceuticals (3.2x), as well as a recapitalization of MEI Pharma. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was obtained during a congressional investigation, likely into financial networks connected to the broader Epstein inquiry.
HOUSE_OVERSIGHT_024024.jpg
This document (page 13, Control Number 257) contains professional biographies for James Niedel and Liam Ratcliffe, executives at New Leaf Venture Partners. It details their educational backgrounds, board memberships, and extensive history in the pharmaceutical industry (GSK and Pfizer respectively), including specific successful drug developments and corporate acquisitions. The document is marked confidential and bears a House Oversight file stamp.
HOUSE_OVERSIGHT_025890.jpg
This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.
HOUSE_OVERSIGHT_016124.jpg
This document is page 14 of a Merrill Lynch research report dated June 30, 2016, discussing Saudi Arabia's National Transformation Program (NTP). It analyzes the risks of economic diversification and highlights Deputy Crown Prince Mohammed bin Salman's visit to the US, detailing agreements reached with major US corporations such as Six Flags, Pfizer, and Microsoft. The document bears a House Oversight Committee Bates stamp.
HOUSE_OVERSIGHT_026364.jpg
This article discusses the new cholesterol drug, Praluent, from Regeneron and Sanofi, focusing on its high price, which is 46% higher than analyst forecasts. It details the FDA's approval for a broader patient group than expected, the potential for wide prescription by doctors despite the label, and the expected resistance from insurance companies who will likely restrict its use. The article also includes commentary from executives at Regeneron and Sanofi, as well as analysts and cardiologists, on the drug's market potential and place alongside existing treatments like statins.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity